4-Substituted Phenyl-Triazine Derivatives for Trk Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases characterized by impaired neurotrophin signaling, such as Alzheimer's disease, lack effective small molecule compounds that can selectively modulate TrkA and TrkB receptors, and existing compounds face challenges in crossing the blood-brain barrier and have limited potency and selectivity.
Innovation Solution
Development of specific 4-substituted phenyl-1,3,5-triazine derivatives that act as positive modulators of Trk receptors, including TrkA, TrkB, and TrkC, and receptor tyrosine kinases like IGF1R and FGFR1, which can cross the blood-brain barrier and enhance neurotrophin signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing small molecule compounds are used to modulate Trk receptors, then some neurotrophin signaling can be enhanced, but the compounds lack sufficient potency and selectivity for effective treatment
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular parameters of phenyl-1,3,5-triazine derivatives, including substituent types (R1-R6 groups), their positions, and chemical properties. This allows optimization of binding affinity to TrkA/TrkB receptors and selective modulation of neurotrophin signaling pathways, achieving improved potency and selectivity compared to existing compounds.
Solution Approach 2:
The patent creates composite molecular structures by combining phenyl-1,3,5-triazine core scaffolds with various substituent groups (aromatic, heteroaromatic, alkyl, alkoxy, etc.). This composite approach enables fine-tuning of pharmacological properties to achieve selective Trk receptor modulation while maintaining blood-brain barrier penetration.
2Reliability
If compounds are designed to cross the blood-brain barrier, then brain targeting is improved, but existing compounds still have limited effectiveness in treating neurological disorders
Solution Approach 1:
The patent modifies molecular parameters including molecular weight, lipophilicity (logP), and hydrogen bonding characteristics of the phenyl-1,3,5-triazine derivatives to optimize blood-brain barrier penetration. These parameter changes enable effective brain targeting while maintaining therapeutic efficacy through selective Trk receptor modulation.
3Measurement precision
If selective TrkA and TrkB modulators are developed, then neurotrophin signaling can be precisely controlled, but no such compounds are currently available for clinical use
Solution Approach 1:
The patent applies local quality by creating molecules with specific substituent patterns at defined positions (R1-R6) on the phenyl-1,3,5-triazine core. This localized structural optimization enables selective binding to TrkA and TrkB receptors with different affinities, allowing precise control of neurotrophin signaling pathways that are currently unachievable with existing non-selective compounds.
Data Source
AI summary
There is provided a compound of formula (I), wherein R1, R2, R3, Q1, Q2, Q3, X, A and n are as defined herein, which compounds are useful in the treatment of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease and the like.